A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

~15 mi. (Lexington, Massachusetts, +89 more cities)

Massachusetts General Hospital; Lurie Center for Autism

ER Positive, +1 more biomarker

Breast Carcinoma

giredestrant, +1 more drug

hormone therapy

SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

~16 mi. (Waltham, Massachusetts, +43 more cities)

Orchard Healthcare Research Inc.

RARA Expression

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~19 mi. (Burlington, Massachusetts, +144 more cities)

Lahey Hospital & Medical Center ( Site 0090)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~19 mi. (Burlington, Massachusetts, +269 more cities)

Lahey Hospital and Medical Center

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

~19 mi. (Newton, Massachusetts, +244 more cities)

Dana-Farber Cancer Institute - Chestnut Hill

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~19 mi. (Newton, Massachusetts, +207 more cities)

MGH Newton-Wellesley Hospital's Vernon Cancer Center ( Site 0082)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~19 mi. (Burlington, Massachusetts, +664 more cities)

Lahey Hospital and Medical Center

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

~19 mi. (Burlington, Massachusetts, +825 more cities)

Lahey Hospital and Medical Center

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

~19 mi. (Burlington, Massachusetts, +240 more cities)

Lahey Hospital and Medical Center

Endometrial Adenocarcinoma, +5 more conditions

carboplatin, +2 more drugs

chemotherapy, +1 more type

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~19 mi. (Burlington, Massachusetts, +93 more cities)

Lahey Hospital & Medical Center ( Site 0090)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

~19 mi. (Burlington, Massachusetts, +533 more cities)

Lahey Hospital and Medical Center

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +6 more drugs

chemotherapy, +2 more types

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

~19 mi. (Burlington, Massachusetts, +606 more cities)

Lahey Hospital and Medical Center

CD274 Amplification

Angiosarcoma, +26 more conditions

ipilimumab, +1 more drug

immunotherapy